ASCEplus: Official Statement on Ingredient Labeling

ASCEplus: Official Statement on Ingredient Labeling

ASCEplus: Official Statement on Ingredient Labeling

ASCEplus: Official Statement on Ingredient Labeling

GRAND Medical explains ASCEplus ingredient-label updates to EV terminology and related changes to packaging and marketing materials.

GRAND Medical explains ASCEplus ingredient-label updates to EV terminology and related changes to packaging and marketing materials.

Published |

Published |

Nov 7, 2025

Nov 7, 2025

Category |

Category |

News

News

001

Official Statement: ASCEplus

GRAND Medical Co., Ltd. (the “Company”) is the authorized exclusive distributor in Taiwan for the ASCEplus product series manufactured by ExoCoBio, Korea.

In response to the competent authorities’ latest management principles for the labeling of exosome-related ingredients, under which plant-derived exosomes may currently only be labeled using terms such as “extracellular vesicles,” we issue the following clarification.

The plant-derived ingredient produced by ExoCoBio from Damask rose stem cells is made using a patented process. Its characteristics and composition meet the International Society for Extracellular Vesicles (ISEV) definition and standards for exosomes. ExoCoBio is currently applying through INCI for recognition of a specific lawful ingredient name for exosomes derived from Damask rose stem cells.

To comply with Taiwan’s current management principles and regulatory requirements, the Company is implementing ongoing adjustments, effective immediately. Chinese and English ingredient labels for the ASCEplus series distributed by the Company will be standardized using the lawful term “EV” (Extracellular Vesicles). Official communications, packaging and marketing materials will be revised accordingly.

We ask all partners and users to replace references to “exosomes” on their websites, social media and marketing materials with “EV; extracellular vesicles,” using the appropriate Chinese terminology where applicable. The Company will provide ready-to-use image and text materials to support these updates. Partners and users are responsible for any violations identified by the competent authorities resulting from failure to follow these instructions or from terminology that does not comply with current requirements.

The Company has also received reports that partners may have been reported to the authorities for claims of therapeutic effects. We remind all partners that ASCEplus and other exosome products on the market fall within the scope of the Cosmetic Hygiene and Safety Act and are not products for medical use. Public communications, including websites and social media pages, should avoid wording that states or implies therapeutic effects or medical treatment, to support regulatory compliance and reduce the risk of complaints.

The Company remains committed to developing the ASCEplus brand and providing professional support to partners and users. This commitment was recognized at the Regenerative Aesthetic Exosome Summit (RAES) in Korea in November 2025, where the Company received the RAES Award Distributor Brand Ambassador.

We will continue supporting the long-term development of ASCEplus in Taiwan with integrity and professionalism. We thank our physicians and partners for their continued trust and support. For questions, please contact your Company sales representative.

GRAND Medical Co., Ltd.
November 7, 2025

魔泌聲明
魔泌聲明
Exocobio魔泌聲明

(More News)

GRAND Medical

(More News)